mirtazapine has been researched along with haloperidol in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 13 (54.17) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Alonso, JM; Andrés, JI; Cid, JM; Díaz, A; Fernández, J; Gil, P; Iturrino, L; Megens, A; Sipido, VK; Trabanco, AA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Berendsen, HH; Broekkamp, CL; Pinder, RM | 1 |
| Berk, M; Brook, S; Ichim, C | 1 |
| Poyurovsky, M; Weizman, A | 1 |
| Heiser, P; Krieg, JC; Singh, S; Vedder, H | 1 |
| Hulstijn, W; Ruigt, GS; Sabbe, BG; Verkes, RJ; Wezenberg, E | 1 |
| Felthous, AR; Hoevet, R; Wenger, PJ | 1 |
| Keltner, NL; McGuiness, TM; Steele, D | 1 |
| Mavridis, D; White, IR | 1 |
| Balcı, N; Demir, Y; Gürbüz, M; Küfrevioğlu, Öİ; Özaslan, MS | 1 |
2 review(s) available for mirtazapine and haloperidol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dealing with missing outcome data in meta-analysis.
Topics: Bias; Data Collection; Data Interpretation, Statistical; Depression; Haloperidol; Humans; Meta-Analysis as Topic; Mirtazapine; Models, Statistical; Probability; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Schizophrenia; Treatment Outcome; Uncertainty | 2020 |
2 trial(s) available for mirtazapine and haloperidol
| Article | Year |
|---|---|
Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Mianserin; Mirtazapine; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2001 |
The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions.
Topics: Adult; Affect; Antipsychotic Agents; Arousal; Benzodiazepines; Choice Behavior; Cross-Over Studies; Double-Blind Method; Female; Haloperidol; Histamine H1 Antagonists; Humans; Hypnotics and Sedatives; Lorazepam; Male; Memory; Memory Disorders; Mianserin; Mirtazapine; Olanzapine; Psychological Tests; Psychomotor Performance; Reaction Time; Reference Values; Saccades; Surveys and Questionnaires; Verbal Learning | 2007 |
20 other study(ies) available for mirtazapine and haloperidol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Furans; Heterocyclic Compounds, 4 or More Rings; Humans; In Vitro Techniques; Mice; Psychotropic Drugs; Radioligand Assay; Rats; Stereoisomerism; Structure-Activity Relationship | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Apomorphine; Catalepsy; Dopamine Agonists; Dose-Response Relationship, Drug; Haloperidol; Male; Mianserin; Mice; Mice, Inbred ICR; Mirtazapine; Rats; Rats, Sprague-Dawley | 1998 |
Mirtazapine for neuroleptic-induced akathisia.
Topics: Adrenergic alpha-Antagonists; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Haloperidol; Humans; Male; Mianserin; Mirtazapine; Psychotic Disorders | 2001 |
Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells.
Topics: Actins; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Blood Cells; Clozapine; Glucose Transporter Type 3; Glucose Transporter Type 4; Glucose Transporter Type 5; Haloperidol; Humans; Mianserin; Mirtazapine; Olanzapine; RNA, Messenger; U937 Cells | 2006 |
Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Dreams; Hallucinations; Haloperidol; Humans; Male; Mianserin; Mirtazapine; Psychotic Disorders; REM Sleep Behavior Disorder; Sleep; Sleep, REM; Wakefulness | 2010 |
Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome?
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combination; Fatal Outcome; Female; Haloperidol; Humans; Mianserin; Middle Aged; Mirtazapine; Neuroleptic Malignant Syndrome; Quetiapine Fumarate; Risk Factors; Serotonin Syndrome | 2011 |
Inhibition effects of some antidepressant drugs on pentose phosphate pathway enzymes.
Topics: Antidepressive Agents; Aripiprazole; Citalopram; Erythrocytes; Glucosephosphate Dehydrogenase; Haloperidol; Humans; Mirtazapine; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase | 2019 |